AUTHOR CORRECTION

OPEN

Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

Francisco Cervantes , David M. Ross, Atanas Radinoff, Francesca Palandri , Alexandr Myasnikov, Alessandro M. Vannucchi, Pierre Zachee, Heinz Gisslinger, Norio Komatsu, Lynda Foltz, Francesco Mannelli, Francesco Passamonti , GERALYN Gilotti, Islam Sadek, Ranjan Tiwari, Evren Zor and Haifa Kathrin Al-Ali

© The Author(s), under exclusive licence to Springer Nature Limited 2021

Leukemia (2021) 35:3626; <https://doi.org/10.1038/s41375-021-01396-x>

Correction to: *Leukemia*

<https://doi.org/10.1038/s41375-021-01261-x>

Following the publication of this article, the authors noted a minor error in the patient numbers on the lower axis of Fig. 4, panel A. This has now been corrected and the amended figure included below. This error does not impact the scientific validity of the manuscript or any conclusions drawn in it.

Open Access This article is licensed under a Creative Commons

Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s), under exclusive licence to Springer Nature Limited 2021